Interlink Electronics stock falls 2.17 percent on Nasdaq

Published on 09/25/2026 at 14:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Interlink Electronics stock posted USD 5.18 on September 24, 2026, while second-quarter revenue rose 10.43 percent to USD 3.77 million. Zacks began coverage with Neutral.

LINK, US53578A1051, Illustration mit AI erstellt.

Interlink Electronics stock (ISIN US53578A1051) fell 2.17 percent to USD 5.18 on Nasdaq on September 24, 2026, giving the small sensor maker a market capitalization of USD 81.59 million. The latest operating figures show revenue growth, but the stock remains 48.71 percent below its 52-week high of USD 10.10.

Revenue returns to growth

Stock Analysis reports that Interlink generated USD 3.77 million in revenue in the quarter ended June 30, 2026, an increase of 10.43 percent from the prior year. Trailing-twelve-month revenue reached USD 12.66 million, up 7.85 percent year over year.

The quarter also marked a shift in operating performance. Operating income reached USD 0.3 million in Q2 2026, compared with USD 0.07 million a year earlier, while diluted earnings per share were USD 0.02 for the quarter.

Neutral rating meets execution risk

Zacks initiated coverage with a Neutral recommendation. Its analysis said first-half 2026 gross profit increased 20.9 percent and the net loss narrowed to USD 0.1 million from USD 0.7 million in the comparable period.

The product mix is improving, but the risk profile remains concentrated. Medical and standard-product revenue advanced 30.5 percent and 34.8 percent, respectively, during the first half, while industrial revenue declined 25.8 percent year over year in Q2. Zacks also identified customer concentration, margin sensitivity and industrial-market weakness as counterweights to the growth case.

Stock stays below yearly high

Interlink shares traded between USD 5.00 and USD 5.36 on September 24, 2026, with volume of 29,506 shares. The stock's 52-week low was USD 2.66, placing the latest price 94.74 percent above that level and 48.71 percent below the high.

For investors, the central question is whether improving medical and standard-product demand can offset weaker industrial shipments. The Q2 revenue gain and return to operating profit provide measurable progress, while the Neutral rating highlights the need for sustained execution.